IBIO

iBio, Inc. IBIO

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,866 of 2,925

Why it scores 11Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Jun 30

Net income

$-10.60M

Quarter to Jun 30

Free cash flow

$-6.25M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$60.80M total
Affinity Asset Advisors, LLC
$7.01M+29.0%
Cormorant Asset Management, LP
$6.25MNew
SILVERARC CAPITAL MANAGEMENT, LLC
$6.16M+1457.7%
Vestal Point Capital, LP
$4.55MNew
VANGUARD CAPITAL MANAGEMENT LLC
$3.67M+92.8%
Frazier Life Sciences Management, L.P.
$3.42M0.0%
Ensign Peak Advisors, Inc
$3.21MNew
Woodline Partners LP
$3.11MNew
MILLENNIUM MANAGEMENT LLC
$2.89M+6.6%
CITADEL ADVISORS LLC
$2.42M+44.7%
BALYASNY ASSET MANAGEMENT L.P.
$2.05M+15.8%
BANK OF AMERICA CORP /DE/
$1.96M+286.2%
Ikarian Capital, LLC
$1.67M0.0%
Sio Capital Management, LLC
$1.58M0.0%
MARSHALL WACE, LLP
$1.58M+45.7%
GEODE CAPITAL MANAGEMENT, LLC
$876.6K+29.2%
Walleye Capital LLC
$875.7K+28.8%
Squarepoint Ops LLC
$873.0KNew
NOESIS CAPITAL MANGEMENT CORP
$708.8K+30.0%
TWO SIGMA INVESTMENTS, LP
$701.2K-2.0%
Ally Bridge Group (NY) LLC
$682.8KNew
ADAR1 Capital Management, LLC
$657.2K-20.1%
Verdad Advisers, LP
$523.1K+430.8%
VANGUARD FIDUCIARY TRUST CO
$502.0K+39.9%
BOOTHBAY FUND MANAGEMENT, LLC
$445.2K0.0%
See all 55 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q4 2026
EDGAR

Net Income

Q4 2026
EDGAR

EPS (Diluted)

Q4 2026
EDGAR

ROIC

Q4 2026
EDGAR

Free Cash Flow

Q4 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IBIO

Earnings Per Share

13fpro.ai/company/IBIO

Loading ratio trend…

IBIO key financials by period

Reported revenue, net income and operating margin by fiscal year, from iBio, Inc.'s annual filings on SEC EDGAR.

iBio, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2026$100.0K$-33.0M—
FY 2025$400.0K$-18.4M—
FY 2024$225.0K$-24.9M—
FY 2022$1.9M$-50.3M—
FY 2021$2.4M$-23.2M—
FY 2020$1.6M$-16.4M—
Source: IBIO filings on SEC EDGAR →

IBIO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About iBio, Inc. (IBIO): stock profile, AI score and financials

iBio, Inc. (IBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IBIO at 10.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,866 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q4 2026), iBio, Inc. reports net income of $-10.6M, free cash flow of $-6.2M. Top institutional holders of IBIO by reported 13-F value include Affinity Asset Advisors, Cormorant Asset Management, SILVERARC CAPITAL MANAGEMENT, based on the most recent SEC filings. IBIO trades on the Nasdaq exchange and files with the SEC under CIK 1420720. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for iBio, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1420720 →